Insider · CIK 0001381874
Steven D Rubin
Files at OPK (OPKO HEALTH, INC.), ELOX (Eloxx Pharmaceuticals, Inc.), NAGE (Niagen Bioscience, Inc.), COCP (Cocrystal Pharma, Inc.), ENTX (Entera Bio Ltd.), RDVT (Red Violet, Inc.). First filing Feb 11, 2026, latest Feb 17, 2026.
Steven D Rubin files SEC Form 4 as director and officer at ENTX (Entera Bio Ltd.), and also at OPK (OPKO HEALTH, INC.), ELOX (Eloxx Pharmaceuticals, Inc.), NAGE (Niagen Bioscience, Inc.), COCP (Cocrystal Pharma, Inc.) and 1 more. Since Feb 11, 2026, Steven D Rubin has reported 2 open-market buys worth $19k and 0 open-market sells worth $0, the latest filed on Feb 17, 2026.
A track record needs three past buys with six months of prices behind them; Steven D Rubin has 0, so none is measured yet.
The newest scored trade: bought $7,450 of ENTX on Feb 12, 2026, filed Feb 17, 2026, scored 53 (moderate). In the last 12 months: 2 buys worth $19k and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ENTX: Entera Bio Ltd.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 53Moderate | Entera Bio Ltd. | $7,450 5,000 shares | +50% | +46% from low-52% from high | |
| 46Moderate | Entera Bio Ltd. | $12k 10,000 shares | - | +28% from low-58% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Mar 19, 2025 | RDVT Red Violet, Inc. | 10,000 0.07% of outstanding | $389k | Mar 19, 2025 | none |
Transactions
Every row this insider has filed, 17 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 24, 2026 | NAGE Niagen Bioscience, Inc. | AGrant or award Stock Option (right to buy)derivative | +31,746 | $0.00 | $0 | 31,746 | Jun 26, 2026 |
| Jun 8, 2026 | ELOX Eloxx Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +4,018 | $0.00 | $0 | 4,018 | Jun 10, 2026 |
| Jun 4, 2026 | RDVT Red Violet, Inc. | AGrant or award Common Stock | +2,179 | - | - | 147,767 | Jun 5, 2026 |
| Jan 24, 2026 | ELOX Eloxx Pharmaceuticals, Inc. | MOption exercise Common Stock | +1,875 | - | - | 14,625 | May 8, 2026 |
| Sep 19, 2025 | ELOX Eloxx Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +179,854 | $0.00 | $0 | 179,854 | May 8, 2026 |
| Jan 24, 2026 | ELOX Eloxx Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitsderivative | -1,875 | $0.00 | $0 | 1,875 | May 8, 2026 |
| Feb 12, 2026 | ENTX Entera Bio Ltd. | POpen-market purchase Ordinary Shares, par value NIS 0.0000769 per share | +5,000 | $1.49 | $7,450 | 15,000 | Feb 17, 2026 |
| Feb 9, 2026 | ENTX Entera Bio Ltd. | POpen-market purchase Ordinary Shares, par value NIS 0.0000769 per share | +10,000 | $1.20 | $12k | 10,000 | Feb 11, 2026 |
| Jan 9, 2026 | COCP Cocrystal Pharma, Inc. | AGrant or award Stock Options (Right to Buy)derivative | +16,410 | $0.00 | $0 | 16,410 | Jan 13, 2026 |
| Dec 19, 2025 | RDVT Red Violet, Inc. | AGrant or award Common Stock | +4,450 | - | - | 145,588 | Dec 22, 2025 |
| Jun 24, 2025 | NAGE Niagen Bioscience, Inc. | AGrant or award Stock Option (right to buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Jun 25, 2025 |
| May 27, 2025 | OPK OPKO HEALTH, INC. | AGrant or award Stock Option (Right to Buy)derivative | +437,500 | $0.00 | $0 | 437,500 | May 29, 2025 |
| Jan 24, 2025 | ELOX Eloxx Pharmaceuticals, Inc. | MOption exercise Common Stock | +3,750 | $0.00 | $0 | 15,750 | Jan 28, 2025 |
| Jan 24, 2025 | ELOX Eloxx Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitsderivative | -3,750 | $0.00 | $0 | 3,750 | Jan 28, 2025 |
| Nov 4, 2024 | RDVT Red Violet, Inc. | AGrant or award Common Stock | +8,000 | - | - | 151,138 | Nov 5, 2024 |
| Oct 16, 2024 | ELOX Eloxx Pharmaceuticals, Inc. | AGrant or award Common Stock | +12,000 | $0.00 | $0 | 12,000 | Oct 17, 2024 |
| Oct 9, 2024 | COCP Cocrystal Pharma, Inc. | AGrant or award Common Stock | +18,957 | - | - | 2,660,242 | Oct 11, 2024 |
Questions about Steven D Rubin
Answered from the filings on this page, as of the latest one.
Is Steven D Rubin buying or selling?
In the last 12 months Steven D Rubin reported 2 open-market buys worth $19k and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $7,450 of ENTX on Feb 12, 2026. Grants, option exercises and tax withholding are not counted.
How did Steven D Rubin's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Steven D Rubin has 0.
Where does Steven D Rubin file Form 4?
Steven D Rubin has filed Form 4 at ENTX (Entera Bio Ltd.); OPK (OPKO HEALTH, INC.) as Executive VP-Administration; ELOX (Eloxx Pharmaceuticals, Inc.); NAGE (Niagen Bioscience, Inc.); COCP (Cocrystal Pharma, Inc.) and 1 more. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.